Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 3/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 5/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490521 | 1.00 | CYP3A4 (0.59) | CYP3A4CRBNALDH1A1LMNAKIT | |
| SCHEMBL1542974 | 0.90 | CYP3A4 (0.61) | CYP3A4CRBNKITNR3C1KIF11 | |
| SCHEMBL1764409 | 0.90 | CYP3A4 (0.61) | CYP3A4CRBNKITNR3C1KIF11 | |
| SCHEMBL482574 | 0.89 | CYP3A4 (0.75) | CYP3A4CRBNALDH1A1LMNATYMS | |
| SCHEMBL482573 | 0.89 | CYP3A4 (0.75) | CYP3A4CRBNALDH1A1LMNATYMS | |
| SCHEMBL2509935 | 0.87 | CYP3A4 (0.57) | CYP3A4CRBNALDH1A1LMNABRD4 | |
| SCHEMBL2509939 | 0.87 | CYP3A4 (0.57) | CYP3A4CRBNALDH1A1LMNABRD4 | |
| SCHEMBL2745167 | 0.85 | CYP3A4 (0.58) | CYP3A4CRBNALDH1A1LMNABRD4 | |
| SCHEMBL2745165 | 0.85 | CYP3A4 (0.58) | CYP3A4CRBNALDH1A1LMNABRD4 | |
| SCHEMBL1764958 | 0.83 | CYP3A4 (0.66) | CYP3A4CRBNALDH1A1LMNABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2379534-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | CYP3A4 978/4885CRBN 1341/4885ALDH1A1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.